Companies Dominating the Biosensors Landscape
- Bio-Rad Laboratories Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Medtronic
- LifeScan, Inc.
- QTL Biodetection LLC
- Molecular Devices Corp.
- Nova Biomedical
- Molex LLC
- Biosensors International Group, Ltd.
- Pinnacle Technologies Inc.
- DuPont Biosensor Materials
- Johnson & Johnson
- Zimmer & Peacock AS
- The Cultivated B. GmbH
- Versarien Plc
- DexCom, Inc.
The market is witnessing a boost in technological development and worldwide adoption with the integration of AI and increasing availability of over-the-counter (OTC) products. Thus, key players are upgrading their pipeline with new features to cope and align with the transition. For instance, in August 2024, DexCom made its OTC glucose biosensor, Stelo, available for general consumers through its e-commerce site, Stelo.com. The company’s strategic expansion in the U.S. is expected to generate greater revenue by captivating one of the largest diabetic populations in the world. Simultaneously, during the same timeline, Monod Bio secured a USD 25.0 million fund to accelerate the development of molecular biosensors for both health and industrial applications. This cohort of innovators include:
